The popularity of Sildenafil initially sparked a boom for pharma, but recent developments present a complicated outlook for shareholders. Lower-cost alternatives are eating into earnings, and ongoing legal battles add https://aliviangwd988393.get-blogging.com/41615199/viagra-and-big-pharma-a-risky-investment